Neuphoria Therapeutics Inc.
NEUP
$4.84
-$0.11-2.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 662.70K | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -48.40K | -47.30K | -- |
| Total Revenue | 662.70K | -- | -48.40K | -47.30K | -- |
| Cost of Revenue | 1.74M | 1.90M | -2.58M | -2.52M | 2.03M |
| Gross Profit | -1.07M | -1.90M | 2.53M | 2.47M | -2.03M |
| SG&A Expenses | 2.63M | 1.67M | 2.18M | 2.23M | 2.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.06M | 3.57M | 4.27M | 4.37M | 4.46M |
| Operating Income | -3.40M | -3.57M | -4.31M | -4.42M | -4.46M |
| Income Before Tax | -1.93M | -937.00K | -2.63M | -2.74M | -4.59M |
| Income Tax Expenses | 11.60K | -132.20K | -8.10K | -8.90K | -34.80K |
| Earnings from Continuing Operations | -1.94M | -804.80K | -2.62M | -2.74M | -4.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.94M | -804.80K | -2.62M | -2.74M | -4.55M |
| EBIT | -3.40M | -3.57M | -4.31M | -4.42M | -4.46M |
| EBITDA | -3.23M | -3.40M | -4.20M | -4.34M | -4.29M |
| EPS Basic | -1.23 | 0.00 | 0.00 | 0.00 | -5.31 |
| Normalized Basic EPS | -0.77 | 0.00 | 0.00 | 0.00 | -3.35 |
| EPS Diluted | -1.23 | 0.00 | 0.00 | 0.00 | -5.31 |
| Normalized Diluted EPS | -0.77 | 0.00 | 0.00 | 0.00 | -3.35 |
| Average Basic Shares Outstanding | 1.58M | 2.81B | 1.89B | 1.89B | 857.30K |
| Average Diluted Shares Outstanding | 1.58M | 2.81B | 1.89B | 1.89B | 857.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
